Journal article icon

Journal article

Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic

Abstract:
Background: The swift development of coronavirus disease 2019 (COVID-19) vaccines marked a monumental effort in global coordination and collaboration; however, there remained major disparities in vaccine access and research capacity across countries. Unequal participation in vaccine development studies from low- and middle- income countries (LMICs) clearly signaled an urgent need to strengthen health research infrastructure in those regions. Methods: With funding from the Gates Foundation (GF), this site readiness initiative carried out rapid capacity enhancement activities to enable large-scale, Phase 3 pivotal clinical trial conduct in LMICs. The International Vaccine Institute (IVI) worked with site partners in four countries (Mozambique, Ghana, Nepal, and the Philippines) after conducting feasibility assessments for site selection. Site-specific gaps were identified, and capacity building activities focused on staff training, site infrastructure, and resource mobilization were carried out over roughly 7 months from October 2020 to May 2021. Results: Despite pandemic-related challenges such as supply chain shortages, by the end of the capacity building efforts all sites were either contracted to or in discussions with trial sponsors to conduct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine studies. This article provides an overview of the site selection process, critical components of site establishment, and final site readiness evaluations carried out amidst a global health emergency. Conclusions: This experience illustrates the value of research capacity enhancement as essential to both pandemic preparedness and global health equity. The lessons learned are being carried into an ongoing initiative across West Africa, currently underway as the “Advancing Research Capabilities in West Africa (ARC-WA).”
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/cid/ciaf094

Authors


More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-9585-3556
More by this author
Role:
Author
ORCID:
0000-0003-4005-8605
More by this author
Role:
Author
ORCID:
0000-0002-2344-4574


More from this funder
Funder identifier:
https://ror.org/0456r8d26


Publisher:
Oxford University Press
Journal:
Clinical Infectious Diseases More from this journal
Volume:
80
Issue:
Supplement_1
Pages:
S1-S8
Publication date:
2025-07-22
DOI:
EISSN:
1537-6591
ISSN:
1058-4838


Language:
English
Keywords:
Source identifiers:
3137044
Deposit date:
2025-07-22
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP